Literature DB >> 1568572

Increased interleukin-2 messenger RNA in the intestinal mucosal lesions of Crohn's disease but not ulcerative colitis.

G E Mullin1, A J Lazenby, M L Harris, T M Bayless, S P James.   

Abstract

Crohn's disease (CD) is characterized by granulomatous inflammation of the intestinal mucosa, but the etiology and pathogenesis of the inflammatory lesions are unknown. The aim of this study was to determine whether T-cell activation and lymphokine production occurs in the mucosal lesions of this disease. Total cellular RNA was isolated from peripheral blood lymphocytes and from colonoscopic mucosal biopsies of normal individuals and patients with CD of the colon or ulcerative colitis (UC). Levels of interleukin-2 (IL-2) messenger RNA (mRNA) transcripts in samples were determined using a quantitative reverse transcriptase polymerase chain reaction method. IL-2 mRNA transcripts were detected in histologically normal intestinal mucosal biopsies obtained from control subjects. In CD, higher levels of IL-2 mRNA transcripts were detected in the mucosa from areas of active inflammation, but in areas that were histologically normal, levels were similar to control subjects. The levels of IL-2 mRNA transcripts in biopsies from active and inactive UC were similar to control subjects. Levels of IL-2 mRNA in peripheral blood lymphocytes were low and not significantly different in all groups of subjects. In conclusion, the normal intestinal mucosa contains IL-2 mRNA transcripts and may be an important source of IL-2. Furthermore, the inflammatory lesions of CD, but not UC, have higher levels of IL-2 mRNA transcripts, suggesting that T-cell activation and lymphokine secretion in the intestine may be important in the pathogenesis of CD. These data provide further evidence that the pathogenesis of CD and UC are different.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1568572     DOI: 10.1016/0016-5085(92)91722-g

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  44 in total

1.  Divergent cell cycle kinetics underlie the distinct functional capacity of mucosal T cells in Crohn's disease and ulcerative colitis.

Authors:  A Sturm; A Z A Leite; S Danese; K A Krivacic; G A West; S Mohr; J W Jacobberger; C Fiocchi
Journal:  Gut       Date:  2004-11       Impact factor: 23.059

2.  Defective expression of gp180, a novel CD8 ligand on intestinal epithelial cells, in inflammatory bowel disease.

Authors:  L S Toy; X Y Yio; A Lin; S Honig; L Mayer
Journal:  J Clin Invest       Date:  1997-10-15       Impact factor: 14.808

3.  Protein microarray analysis of disease activity in pediatric inflammatory bowel disease demonstrates elevated serum PLGF, IL-7, TGF-beta1, and IL-12p40 levels in Crohn's disease and ulcerative colitis patients in remission versus active disease.

Authors:  Howard A Kader; Velizar T Tchernev; Ebenezer Satyaraj; Serguei Lejnine; Gregory Kotler; Stephen F Kingsmore; Dhavalkumar D Patel
Journal:  Am J Gastroenterol       Date:  2005-02       Impact factor: 10.864

4.  Contribution of the IL-2 and IL-10 genes to inflammatory bowel disease (IBD) susceptibility.

Authors:  M Parkes; J Satsangi; D Jewell
Journal:  Clin Exp Immunol       Date:  1998-07       Impact factor: 4.330

5.  Poor diagnostic value of colonic CD44v6 expression and serum concentrations of its soluble form in the differentiation of ulcerative colitis from Crohn's disease.

Authors:  W Reinisch; K H Heider; G Oberhuber; C Dejaco; M Müllner; G R Adolf; C Gasché
Journal:  Gut       Date:  1998-09       Impact factor: 23.059

6.  Serum levels of soluble CD30 are increased in ulcerative colitis (UC) but not in Crohn's disease (CD).

Authors:  R Giacomelli; A Passacantando; I Parzanese; P Vernia; N Klidara; F Cucinelli; R Lattanzio; E Santori; P Cipriani; R Caprilli; G Tonietti
Journal:  Clin Exp Immunol       Date:  1998-03       Impact factor: 4.330

7.  Patients with inflammatory bowel disease may have a transforming growth factor-beta-, interleukin (IL)-2- or IL-10-deficient state induced by intrinsic neutralizing antibodies.

Authors:  E C Ebert; A Panja; K M Das; R Praveen; X Geng; C Rezac; M Bajpai
Journal:  Clin Exp Immunol       Date:  2009-01       Impact factor: 4.330

8.  Adequacy of mucosal biopsies for evaluation of intestinal cytokine-specific mRNA. Comparative study of RT-PCR in biopsies and isolated cells from normal and inflamed intestine.

Authors:  K Fukushima; G West; C Fiocchi
Journal:  Dig Dis Sci       Date:  1995-07       Impact factor: 3.199

9.  Cytokine messenger RNA expression and proliferation status of intestinal mononuclear cells in noninflamed gut and Crohn's disease.

Authors:  F Autschbach; G Schürmann; L Qiao; H Merz; R Wallich; S C Meuer
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

10.  An increased risk of Crohn's disease in individuals who inherit the HLA class II DRB3*0301 allele.

Authors:  D G Forcione; B Sands; K J Isselbacher; A Rustgi; D K Podolsky; S Pillai
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.